IL2RA and neoplasm: All three peptides were found to bind CD25 with KD values ranging from 30 to 40 nM, which are higher than that of daclizumab (~ 1 nM), but are within a clinically relevant range and may potentially elicit less “on-target off-tumor” adverse effects24–31.